Biomarin Pharmaceutical

Biomarin Pharmaceutical

Quarterly Financials

Values in thousands2026-06-302026-03-312025-12-312025-09-30
Revenue
$989,708
$766,208
$874,565
$776,133
Gross Profit
786,913
571,209
579,470
636,048
EBITDA
222,317
172,572
-3,937
-5,258
EBIT
124,679
156,161
-24,375
-23,745
Net Income
44,762
105,527
-46,573
-30,744
Net Change In Cash
989,708
766,208
874,565
776,133
Free Cash Flow
139,293
199,728
58,922
334,935
Cash
874,005
2,222,435
1,311,679
1,250,108
Basic Shares
194,147
197,671
197,394
192,032

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$3,221,253
$2,853,915
$2,419,226
$2,096,039
Gross Profit
2,484,425
2,273,680
1,887,164
1,593,016
EBITDA
572,936
650,528
306,773
265,359
EBIT
493,379
554,102
202,387
163,390
Net Income
348,901
426,859
167,645
141,561
Net Change In Cash
3,221,253
2,853,915
2,419,226
2,096,039
Free Cash Flow
724,956
475,423
51,648
54,943
Cash
1,311,679
942,842
755,127
724,531
Basic Shares
197,394
196,708
191,595
188,963

Earnings Calls

QuarterEPS
2026-06-30
$0.90
2026-03-31
$0.76
2025-12-31
$0.46
2025-09-30
$0.12